LYELL IMMUNOPHARMA INC (LYEL) Stock News

USA - NASDAQ:LYEL - US55083R2031 - Common Stock

15.8 USD

-0.75 (-4.53%)

Last: 10/2/2025, 3:31:53 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

LYEL Latest News, Press Relases and Analysis

All

Press Releases

6 days ago - By: Benzinga - Mentions: UTHR FHN VMI SYRE

This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

a month ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

a month ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

a month ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in September Investor Conferences

2 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

2 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

2 months ago - By: Benzinga - Mentions: OPK ATEC MBRX BIO ...

12 Health Care Stocks Moving In Thursday's After-Market Session

2 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

2 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

3 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

3 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

4 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

4 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

4 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

4 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

4 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

4 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

5 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

5 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

5 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

5 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

6 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

6 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

7 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

7 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

8 months ago - By: Lyell Immunopharma, Inc

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

9 months ago - By: Lyell Immunopharma, Inc

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

9 months ago - By: Lyell Immunopharma, Inc

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

10 months ago - By: Lyell Immunopharma, Inc

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting